Utilizing those schedules, DTA-1 addition enhanced tumor protection/regression and those effects were attributed to enhanced costimulation of CD4+FoxP3- and CD8+ effector T cells with the simultaneous inhibition of Treg suppression. The gene discussed is FOXP3; the disease is neoplasm.